A targeted stereotactic body radiotherapy strategy showed potential to extend control in early-stage breast cancer spread, according to findings presented at the ESTRO Congress 2026. The approach targets oligometastatic lesions—patients whose cancer has started to metastasize but remains limited in burden—with the aim of improving progression-free outcomes. The presentation highlights a renewed focus on radiotherapy as more than palliative care, emphasizing precision targeting to keep disease in check while limiting exposure to surrounding tissue. Clinical impact will hinge on how progression-free survival and safety compare with existing standards in the patient population studied. The excerpt does not provide trial design specifics, but the congress venue and the focus on oligometastatic disease mark a notable development for radiation oncology pipelines.